FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept - Seite 3

About Sandoz
Sandoz, a Novartis company, is a global leader in generic pharmaceuticals, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable, primarily off-patent products to patients and customers around the globe.
The Sandoz global portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz holds the global #1 position in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines.
Nearly half of Sandoz's portfolio is in differentiated products - products that are scientifically more difficult to develop and manufacture than standard generics.

In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has consistently driven growth in selected geographies and differentiated product areas through a series of targeted acquisitions.

* Enbrel is a registered trademark of Amgen Inc.

References
[1] American College of Rheumatology. http://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditio ... (Last accessed 13 September 2015)
[2] National Psoriasis Association. https://www.psoriasis.org/cure_known_statistics (Last accessed 13 September 2015)

# # #

For further information:

Eric Althoff Novartis Global Media Relations [phone] [phone] [e-mail]	Sreejit Mohan Sandoz Global Communications [phone] [e-mail]

Leslie Pott
Sandoz US Communications
[phone]
[phone]
[e-mail]

Novartis Investor Relations

Central phone:	[phone]	North America:
Samir Shah	[phone]	Richard Pulik	[phone]
Pierre-Michel Bringer	[phone]	Sloan Pavsner	[phone]
Thomas Hungerbuehler	[phone]
Isabella Zinck	[phone]
e-mail: [e-mail]

©2015 Sandoz Inc. All rights reserved.